C4 Therapeutics Director Utpal Koppikar Granted 62,000 Stock Options

Utpal Koppikar, a director of C4 Therapeutics, Inc., was granted 62,000 stock options on June 24, 2026, with an exercise price of $4.25 per share. The options have a 10-year term expiring on June 23, 2036. According to the filing, these options will vest in full upon the earlier of either June 24, 2027, or the next annual meeting of the company's stockholders, subject to Koppikar's continued service as a board member on that date. The transaction was reported on Form 4 and represents a standard equity compensation grant to a non-employee director. The filing indicates this is a direct ownership transaction with no purchase price for the grant itself, as is typical for stock option awards.